Report cover image

Biological Therapies for Cancer: Technologies and Global Markets

Publisher BCC Research
Published Nov 03, 2025
Length 139 Pages
SKU # WA20580213

Description

Report Scope

This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.

The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025–2030 for the forecast years.

Report Includes
  • 43 data tables and 53 additional tables
  • An analysis of the global markets for biological therapies for cancer treatment and related technologies
  • Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
  • Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
  • Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
  • Impact analysis of the U.S. tariff laws on the market
  • Insights derived from Porter’s Five Forces model, as well as global supply chain
  • A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
  • Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
  • A relevant patent analysis, featuring key granted and published patents
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
  • Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson


Companies Mentioned

Amgen Inc.
Astrazeneca
Bayer Ag
Biontech Se
Bristol-myers Squibb Co.
F. Hoffmann-la Roche Ltd.
Gsk Plc
Incyte
Innate Pharma Inc.
Johnson & Johnson
Lilly Usa Llc
Merck & Co. Inc.
Novartis Ag
Pfizer Inc.
Sanofi

Table of Contents

139 Pages
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Technological Advances
Market Dynamics and Growth Factors
Segmental Analysis
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Key Modalities and Mechanisms of Action
Porter's Five Forces Model
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Competition in the Industry
Threat of Substitutes
Macroeconomic Factors Analysis
Aging Population Driving Cancer Incidence and Demand for Biologics
Rising Healthcare Expenditures and Oncology Drug Spending
Impact of the U.S. Tariff Scenario
Pricing Strategies for Cancer Biologics
Value-Based Pricing
Premium Pricing for Innovation
Indication-Based Pricing
Market Access and Tiered Pricing
Competitive Benchmarking
Cancer Drug Costs
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Biosimilars in Europe
Issues with Biosimilars
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Global Cancer Incidence
Advances in Immuno-Oncology and Targeted Therapies
Shift Towards Personalized and Precision Medicine
Market Restraints
High Treatment Costs
Stringent Manufacturing and Regulatory Requirements
Market Opportunities
Expanding Indications for Approved Biologics
Technological Advances in Biologics Manufacturing
Chapter 4 Regulatory Landscape
Biological Therapies for Cancer Industry Regulatory Scenario
Overview
U.S.
EU
Japan
China
India
Medicare Coverage and Reimbursement for Cancer Care
Chapter 5 Emerging Technologies and Developments
Overview
Next-Generation Antibody-Drug Conjugates (ADCs)
Bispecific and Multispecific Antibodies
Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
Allogeneic (“Off-the-Shelf”) Cell Therapies
Artificial Intelligence (AI) in Biological Cancer Therapies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis for Biological Therapies for Cancer by Product Type
Monoclonal Antibodies
Vaccines
CAR T-cell Therapy
Cancer Growth Blockers
Immune Checkpoint Inhibitors
Other (Blood Cell Growth Factors, Cytokines)
Market Analysis of Biological Therapies for Cancer by Cancer Type
Epidemiology by Cancer Type/Site
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other (Blood, Skin, Ovarian, Rare Cancer)
Geographic Breakdown
Global Biosimilars Market by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Cancer Clinical Trials and Biologics in Development
Overview
Key Pipeline Drugs by Company
Chapter 8 Competitive Landscape
Overview
Biological Therapy for Cancer Market: Major Players
Chapter 9 Appendix
Methodology
References
Abbreviations
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BIONTECH SE
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC
INCYTE
INNATE PHARMA INC.
JOHNSON & JOHNSON
LILLY USA LLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us